Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer

Zsuzsanna Nagy^{1

2

3}, Rinath Jeselsohn^{1

2

3

4}

Affiliations

¹ Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
³ Department of Medicine, Harvard Medical School, Boston, MA, United States.
⁴ Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

Published Erratum

Zsuzsanna Nagy et al. Front Oncol. 2023.

. 2023 Mar 6:13:1155540.

doi: 10.3389/fonc.2023.1155540. eCollection 2023.

Zsuzsanna Nagy^{1

2

3}, Rinath Jeselsohn^{1

2

3

4}

¹ Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
³ Department of Medicine, Harvard Medical School, Boston, MA, United States.
⁴ Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.1037531.].

Keywords: ESR1 fusion; SERD; breast cancer; endocrine therapy resistance; estrogen receptor.

ESR1 fusions and therapeutic resistance in metastatic breast cancer.
Nagy Z, Jeselsohn R. Nagy Z, et al. Front Oncol. 2023 Jan 4;12:1037531. doi: 10.3389/fonc.2022.1037531. eCollection 2022. Front Oncol. 2023. PMID: 36686845 Free PMC article. Review.